Exhibit 99.3

 

SHINECO, INC.

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

 

Introduction

 

On April 22, 2025, Shineco, Inc. (the “Company”), through its wholly-owned subsidiary, Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life Science”), entered into a share purchase agreement (the “SPA”) with Dr. Lim Kah Meng (“Seller”), the sole shareholder of InfiniClone Limited, a company incorporated under the laws of Hong Kong (“InfiniClone”). Pursuant to the SPA, Shineco Life Science would acquire 51% of the equity interests of InfiniClone from the Seller (the “Acquisition”). As the consideration for the acquisition, the Company (a) shall pay the Seller US$19,895,600 in cash; and (b) shall issue 3,450,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”) to the Seller.

 

The following unaudited pro forma condensed combined financial information is presented to illustrate the estimated pro forma effect of the Acquisition.

 

The unaudited pro forma condensed combined financial information presented has been prepared in accordance with Article 11 of Regulation S-X, Pro Forma Financial Information, as amended by the SEC’s final rule, Release No. 33-10786 “Amendments to Financial Disclosures about Acquired and Disposed Businesses.” Release No. 33-10786 replaces the pro forma adjustment criteria with simplified requirements to depict the accounting for the transaction (“Transaction Accounting Adjustments”) and the option to present the reasonably estimable synergies and other transaction effects that have occurred or are reasonably expected to occur (“Management’s Adjustments”). The Company has elected not to present Management’s Adjustments and has only presented Transaction Accounting Adjustments in the following unaudited pro forma condensed combined financial information.

 

The unaudited proforma condensed combined balance sheet as of March 31, 2025, together with the unaudited condensed combined statements of operations for the year ended June 30, 2024 and for the nine months ended March 31, 2025 presented herein gives effect to the Acquisition as if the transaction had occurred at the beginning of such periods and includes certain adjustments that are directly attributable to the transaction which are expected to have a continuing impact on the Company, and are factually supportable, as summarized in the accompanying notes and assumptions.

 

The pro forma adjustments and allocation of the Purchase Price are preliminary, are based on management’s current estimates of the fair value of the assets to be acquired and liabilities to be assumed, and are based on currently available information, including preliminary work performed by independent valuation specialists.

 

As of the date hereof, we have not completed the detailed valuation analysis and calculations necessary to arrive at final estimates of the fair market value of the assets of InfiniClone to be acquired and the liabilities to be assumed and the related allocations of the Purchase Price. Accordingly, certain of InfiniClone’s assets and liabilities are presented at their respective carrying amounts and should be treated as preliminary values.

 

Actual results will differ from the unaudited pro forma condensed combined financial information provided herein once we have completed the valuation analysis necessary to finalize the required Purchase Price allocations and identified any additional conforming accounting policy changes for InfiniClone. There can be no assurance that such finalization will not result in material changes to the unaudited pro forma condensed combined financial information presented.

 

Assumptions and estimates underlying the unaudited pro forma adjustments set forth in the unaudited pro forma condensed combined financial statements are described in the accompanying notes below.

 

The unaudited pro forma condensed combined financial information and accompanying notes are based on, and should be read in conjunction with, (i) the historical audited consolidated financial statements of the Company and accompanying notes for the year ended June 30, 2024, included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2024; and the historical unaudited consolidated financial statements of the Company and accompanying notes for the period ended March 31, 2025, included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and (ii) the historical audited financial statements of InfiniClone and accompanying notes included for the year ended June 30, 2024, and the historical unaudited financial statements of InfiniClone and accompanying notes for the nine months period ended March 31, 2025, each of which are filed as Exhibits 99.1 and 99.2, respectively, with this Current Report on Form 8-K/A.

 

 

 

 

The following unaudited pro forma condensed combined financial statements are provided for illustrative purposes only and are based on currently available information and assumptions that we believe are reasonable under the circumstances. They do not purport to represent what our actual consolidated results of operations or the consolidated financial position would have been had the Acquisition been completed on the dates indicated, or on any other date, nor are they necessarily indicative of our future consolidated results of operations or consolidated financial position as a result of the Acquisition. Our actual financial position and results of operations will differ, perhaps significantly, from the pro forma amounts reflected herein due to a variety of factors, including access to additional information, changes in value not currently identified and changes in operating results of the Company and InfiniClone following the date of the unaudited pro forma condensed combined financial statements.

 

SHINECO, INC.

UNAUDITED PROFORMA CONDENSED COMBINED BALANCE SHEET

AS OF MARCH 31, 2025

 

   SHINECO, INC.   INFINICLONE   Pro Forma
Adjustments
   Note  Pro Forma
Combined
 
ASSETS                      
                        
CURRENT ASSETS:                      
Cash and cash equivalents  $192,735   $649   $(6)  (e)  $193,378 
Accounts receivable, net   317                 317 
Due from related parties, net   24,456    374            24,830 
Inventories, net   204,470    493,836            698,306 
Advances to suppliers, net   1,011                 1,011 
Other current assets, net   12,132,571                 12,132,571 
Current assets held for discontinued operations   22,363,220                 22,363,220 
TOTAL CURRENT ASSETS   34,918,780    494,859    (6)      35,413,633 
                        
Property and equipment, net   73,008    22,118,724    1,255,187   (f) (g)   23,446,919 
Intangible assets, net   9,849,888         22,357,250   (a) (h)   32,207,138 
Goodwill   2,018,747         1,736,248   (b)   3,754,995 
Operating lease right-of-use   68,729                 68,729 
Non-current assets held for discontinued operations   38,573,393                 38,573,393 
TOTAL ASSETS  $85,502,545   $22,613,583   $25,348,679      $133,464,807 
                        
LIABILITIES AND EQUITY                       
                        
CURRENT LIABILITIES:                       
Short-term bank loans  $1,747,681   $   $      $1,747,681 
Accounts payable   78,715                 78,715 
Contract liabilities   26,958                 26,958 
Due to related parties   254,125    20,174            274,299 
Other payables and accrued expenses   4,685,444         19,895,600   (i)   24,581,044 
Operating lease liabilities - current   306,236                 306,236 
Convertible note payable - current   9,741,322                 9,741,322 
Taxes payable   662,587                 662,587 
Deferred income   31,099,110                 31,099,110 
TOTAL CURRENT LIABILITIES   48,602,178    20,174    19,895,600       68,517,952 
                        
Income tax payable - noncurrent portion   186,191                 186,191 
Operating lease liabilities - non-current   6,137                 6,137 
Long-term bank loans - non-current   1,000,597                 1,000,597 
Deferred tax liabilities   9,646,807         4,014,114   (j)(m)   13,660,921 
TOTAL LIABILITIES   59,441,910    20,174    23,909,714       83,371,798 
                        
Commitments and contingencies                     - 
                        
SHAREHOLDERS’ EQUITY (DEFICIT)                       
Common stock; par value $0.001, 150,000,000 shares authorized 2,179,844 and 332,215 shares issued and outstanding at March 31, 2025 and June 30, 2024   17,346    380    3,070   (c)   20,796 
Additional paid-in capital   123,281,225    24,098,201    (19,961,651)  (c)(d)   127,417,775 
Subscription receivable   (36,192,350)                (36,192,350)
Statutory reserve   4,350,297                 4,350,297 
Accumulated deficit   (73,102,508)   (1,127,996)   346,421   (e)(d)(g)(h)(m)   (73,884,083)
Accumulated other comprehensive gain (loss)   (189,035)   (377,176)   377,176   (k)   (189,035)
TOTAL SHAREHOLDERS’ EQUITY (DEFICIT)   18,164,975    22,593,409    (19,234,984)      21,523,400 
Non-controlling interest   7,895,660         20,673,949   (k)   28,569,609 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)  $85,502,545   $22,613,583   $25,348,679      $133,464,807 

 

 

 

 

SHINECO, INC.

UNAUDITED PROFORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

FOR THE NINE MONTHS ENDED MARCH 31, 2025

 

 

 

   SHINECO, INC.   INFINICLONE   Pro Forma
Adjustments
   Note  Pro Forma
Combined
 
                    
REVENUE  $259,040                $259,040 
                        
COST OF REVENUE                       
Cost of product and services   135,852                 135,852 
Business and sales related tax   855                 855 
Total cost of revenue   136,707                 136,707 
                        
GROSS INCOME   122,333                 122,333 
                        
OPERATING EXPENSES                       
General and administrative expenses   5,069,621    759,929    1,846,377   (e)(g) (h)   7,675,927 
Research and development expenses   54,602                 54,602 
Selling expenses   88,030                 88,030 
Total operating expenses  $5,212,253    759,929    1,846,377      $7,818,559 
                        
LOSS FROM OPERATIONS   (5,089,920)   (759,929)   (1,846,377)      (7,696,226)
                        
OTHER INCOME (EXPENSE)                       
Gain from disposal of a subsidiary  $114,945                $114,945 
Other income, net   3,505                 3,505 
Amortization of debt issuance costs   (482,664)                (482,664)
Interest expenses, net   (318,001)                (318,001)
Total other expenses   (682,215)                (682,215)
                        
LOSS BEFORE PROVISION FOR INCOME TAXES FROM CONTINUING OPERATIONS   (5,772,135)   (759,929)   (1,846,377)      (8,378,441)
                        
BENEFITS FOR INCOME TAXES   (187,854)        (313,883)  (m)   (501,737)
                        
NET LOSS FROM CONTINUING OPERATIONS   (5,584,281)   (759,929)   (1,532,494)      (7,876,704)
                        
DISCONTINUED OPERATIONS:                       
Loss from discontinued operations, net of taxes   (15,874,674)                (15,874,674)
Gain on disposal of discontinued operations                       
Net loss from discontinued operations   (15,874,674)                (15,874,674)
                        
NET LOSS   (21,458,955)   (759,929)   (1,532,494)      (23,751,378)
                        
Net loss attributable to non-controlling interest   (2,693,076)        (750,919)  (n)   (3,443,995)
                        
NET LOSS ATTRIBUTABLE TO SHINECO, INC.   (18,765,879)   (759,929)   (781,575)      (20,307,383)
                        
COMPREHENSIVE LOSS                       
Net loss   (21,458,955)   (759,929)   (1,532,494)      (23,751,378)
Other comprehensive loss: foreign currency translation loss   41,102    204,581            245,683 
Total comprehensive loss   (21,417,853)   (555,348)   (1,532,494)      (23,505,695)
Less: comprehensive loss attributable to non-controlling interest   (2,681,102)        (750,919)  (n)   (3,432,021)
                        
COMPREHENSIVE LOSS ATTRIBUTABLE TO SHINECO, INC.  $(18,736,751)   (555,348)   (781,575)     $(20,073,674)
                        
Weighted average number of shares basic and diluted   6,048,079         3,450,000   (l)   9,498,079 
                        
Basic and diluted loss per common share   (3.10)                (2.14)
                        
Loss per common share                       
Continuing operations - Basic and Diluted   (0.84)                (0.47)
Discontinued operations - Basic and Diluted   (2.26)                (1.67)
Net loss per common share - basic and diluted   (3.10)                (2.14)

 

 

 

 

SHINECO, INC.

UNAUDITED PROFORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

FOR THE YEAR ENDED JUNE 30, 2024

 

   SHINECO, INC.   INFINICLONE   Pro Forma
Adjustments
   Note  Pro Forma
Combined
 
                    
REVENUE  $9,801,856   $          $9,801,856 
                        
COST OF REVENUE                       
Cost of product and services   8,905,634                 8,905,634 
Business and sales related tax   14,054                14,054 
Total cost of revenue   8,919,688                8,919,688 
                       
GROSS INCOME   882,168                882,168 
                        
OPERATING EXPENSES                       
General and administrative expenses   17,522,624    367,421    2,439,414   (e)(g) (h)   20,329,459 
Research and development expenses   311,989                 311,989 
Selling expenses   113,426                 113,426 
Total operating expenses  $17,948,039    367,421    2,439,414      $20,754,874 
                        
(LOSS FROM OPERATIONS   (17,065,871)   (367,421)   (2,439,414)      (19,872,706)
                        
OTHER INCOME (EXPENSE)                       
Impairment loss on an unconsolidated entity  $(26,003)  $   $      $(26,003)
Impairment loss on goodwill   (14,824,819)                (14,824,819)
Investment income from derivative financial assets   4,996                 4,996 
Loss from disposal of a subsidiary                       
Other income, net   222,910                 222,910 
Amortization of debt issuance costs   (655,751)                (655,751)
Interest expenses, net   (1,622,346)                (1,622,346)
Total other expenses   (16,901,013)                (16,901,013)
                        
LOSS BEFORE PROVISION FOR INCOME TAXES FROM CONTINUING OPERATIONS   (33,966,884)   (367,421)   (2,439,414)      (36,773,719)
                        
BENEFITS FOR INCOME TAXES   (758,902)        (414,700)  (m)   (1,173,602)
                        
LOSS FROM CONTINUING OPERATIONS   (33,207,982)   (367,421)   (2,024,714)      (35,600,117)
                        
DISCONTINUED OPERATIONS:                       
Loss from discontinued operations, net of taxes   (49,455)                (49,455)
Gain on disposal of discontinued operations   8,904,702                 8,904,702 
Net loss from discontinued operations   8,855,247                 8,855,247 
                        
NET LOSS   (24,352,735)   (367,421)   (2,024,714)      (26,744,870)
                        
Net income (loss) attributable to non-controlling interest   (1,903,718)        (992,110)  (n)   (2,895,828)
                        
NET LOSS ATTRIBUTABLE TO SHINECO, INC.   (22,449,017)   (367,421)   (1,032,604)      (23,849,042)
                        
COMPREHENSIVE LOSS                       
Net loss   (24,352,735)   (367,421)   (2,024,714)      (26,744,870)
Other comprehensive loss: foreign currency translation loss   (3,299)   (581,752)           (585,051)
Total comprehensive loss   (24,356,034)   (949,173)   (2,024,714)      (27,329,921)
Less: comprehensive income (loss) attributable to non-controlling interest   (1,911,859)        (992,110)  (n)   (2,903,969)
                        
COMPREHENSIVE LOSS ATTRIBUTABLE TO SHINECO, INC.  $(22,444,175)   (949,173)   (1,032,604)     $(24,425,952)
                        
Weighted average number of shares basic and diluted   5,318,979         3,450,000   (l)   8,768,979 
                        
Basic and diluted loss per common share   (4.23)                (2.72)
                        
Loss per common share                       
Continuing operations - Basic and Diluted   (5.89)                (3.73)
Discontinued operations - Basic and Diluted   1.66                 1.01 
Net loss per common share - basic and diluted   (4.23)                (2.72)

 

 

 

 

Note 1. Basis of Pro Forma Presentation

 

The unaudited pro forma condensed combined financial statements are derived from the historical consolidated financial statements of the Company and the historical financial statements of InfiniClone. The unaudited pro forma condensed combined financial statements are prepared as a business combination using the purchase accounting method.

 

The unaudited proforma condensed combined balance sheet as of March 31, 2025, together with the unaudited condensed combined statements of operations for the year ended June 30, 2024 and for the nine months ended March 31, 2025 presented herein gives effect to the Acquisition as if the transaction had occurred at the beginning of such periods and includes certain adjustments that are directly attributable to the transaction which are expected to have a continuing impact on the Company, and are factually supportable, as summarized in the accompanying notes and assumptions.

 

The Acquisition will be accounted for under the purchase accounting method of accounting in accordance with FASB ASC 805, Business Combinations, using the fair value concepts defined in ASC 820, Fair Value Measurements and Disclosures. We are treated as the “acquirer” and InfiniClone is treated as the “acquired” company for financial reporting purposes. Accordingly, the purchase consideration allocated to the InfiniClone business’s net assets and liabilities for preparation of the unaudited pro forma condensed combined balance sheet is based upon their estimated preliminary fair values assuming the Acquisition was completed as of March 31, 2025. The amount of the purchase consideration that was in excess of the estimated preliminary fair values of the InfiniClone’s business’s net assets and liabilities at March 31, 2025 is recorded as goodwill in the unaudited pro forma condensed combined balance sheet.

 

We have not yet completed the detailed valuation studies necessary to arrive at the final estimates of the fair value of InfiniClone’s assets to be acquired, the liabilities to be assumed and the related allocations of the Purchase Price.

 

The unaudited pro forma condensed combined financial information includes pro forma adjustments that are (i) directly attributable to the Acquisition, (ii) factually supportable, and (iii) with respect to the unaudited condensed combined pro forma statements of operations, expected to have a continuing impact on the results of operations of the combined company.

 

Actual results may differ from these unaudited pro forma condensed combined financial statements once we have determined the final Purchase Price for InfiniClone and have completed the valuation studies necessary to finalize the required Purchase Price allocations and identified any additional conforming accounting policy changes. There can be no assurance that such finalization will not result in material changes to the unaudited pro forma condensed combined financial information presented. The preliminary unaudited pro forma Purchase Price allocation has been made solely for preparing these unaudited pro forma condensed combined financial statements.

 

These unaudited pro forma condensed combined financial statements do not purport to represent what the actual consolidated results of operations of the Company would have been had the Acquisition been completed on the dates assumed, nor are they necessarily indicative of future consolidated results of operations or consolidated financial position.

 

 

 

 

Note 2. Accounting Policies

 

The unaudited pro forma condensed combined financial statements may not reflect all reclassifications necessary to conform InfiniClone’s presentation to that of the Company’s. As a result, we may identify differences between the accounting policies of the two companies that, when conformed, could have a material impact on the combined financial statements.

 

Note 3. Preliminary Purchase Consideration and Purchase Price Allocation

 

Under the purchase method of accounting, the identifiable assets acquired and liabilities assumed are recorded at the fair values. The Purchase Price allocation provided in these pro forma condensed combined financial statements is preliminary and based on estimates of the fair value as at March 31, 2025.

 

We have engaged a third-party valuation company to assist us with valuation of InfiniClone’s assets and liabilities. The detailed valuation necessary to estimate the fair value of the assets acquired and liabilities assumed has not yet been completed; accordingly, the adjustments to record the assets acquired and liabilities assumed at fair value reflect the best estimate of the Company and are subject to change once additional analyses are completed. There can be no assurance that such third-party valuation work will not result in material changes from the preliminary accounting treatment included in the accompanying unaudited pro forma condensed combined financial statements.

 

The Purchase Price, as provided in the SPA, provides for the Sellers to receive US$19,895,600 in cash consideration and 3,450,000 common shares of the Company.

 

Cash  $19,895,600 
Estimated fair value of common shares issued   4,140,000 
Estimated fair value of consideration transferred  $24,035,600 

 

The table below represents the preliminary allocation of the estimated total Purchase Price to InfiniClone’s business’s assets and liabilities in the Acquisition based on our preliminary estimate of their respective fair values.

 

Description  Estimated
Fair Value
Assets acquired:     
Cash and cash equivalents  $649 
Due from related parties, net   374 
Inventories, net   493,836 
Property and equipment, net   23,407,532 
Intangible assets   24,170,000 
Goodwill   1,736,248 
Total assets acquired   49,808,639 
      
Due to related parties   20,174 
Deferred tax liabilities   4,327,997 
Total liabilities acquired   4,348,171 
Less: non-controlling interest   21,424,868 
Estimated fair value of net assets acquired  $24,035,600 

 

Our unaudited pro forma Purchase Price allocation includes certain identifiable intangible assets with an estimated fair value of approximately US$24,170,000. These intangible assets include exclusive and non-exclusive patent technology, each of which is expected to have a finite life and are expected to be amortized using the straight-line method over the respective lives of each asset.

 

 

 

 

Goodwill represents the amount of the Purchase Price in excess of the estimated preliminary amounts assigned to the fair value of the InfiniClone’s assets acquired and the liabilities assumed. Since these amounts are estimates, the final amount of goodwill recorded may differ materially from the amount presented. Goodwill will not be amortized, but will be tested for impairment at least annually for events or circumstances that may indicate a possible impairment exists. In the event management determines that the value of goodwill has been impaired, we will incur an impairment charge during the period in which the determination is made.

 

The preliminary fair value of the identifiable intangible assets acquired was estimated using a combination of different methods under the Cost-Based Approach. The Cost-Based Approach is a general way of determining a value indication of a business, business ownership interest, security, or intangible asset by using one or more methods that convert anticipated economic benefits into a present single amount. This valuation technique requires us to make certain assumptions about future operating and financial performance and cash flow, and other such variables which are discounted to present value using a discount rate that reflects the risk factors associated with future cash flow, the characteristics of the assets acquired, the relationship between the assets acquired and the business as a whole, and the experience of the acquired business. Such valuation methodologies and estimates are subject to change, possibly materially, as additional information becomes available and as additional analyses are performed.

 

This preliminary unaudited pro forma Purchase Price allocation has been made solely for the purpose of preparing these unaudited pro forma condensed combined financial statements. The final total consideration and amounts allocated to InfiniClone’s acquired assets and assumed liabilities could differ materially from the preliminary amounts presented in these unaudited pro forma condensed combined financial statements. A decrease in the fair value of the assets or an increase in the fair value of the liabilities from the preliminary valuations presented would result in a dollar-for-dollar corresponding increase in the amount of goodwill that will result from the Acquisition. In addition, if the value of the property and equipment and identifiable intangible assets is higher than the amounts included in these unaudited pro forma condensed combined financial statements, it may result in higher depreciation and amortization expense than is presented in the unaudited pro forma condensed combined statements of operations. Any such increases could be material and could result in our actual future financial condition and results of operations differing materially from those presented in the unaudited pro forma condensed combined financial statements.

 

Note 4. Adjustments to Unaudited Pro Forma Condensed Combined Financial Statements

 

The unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the Acquisition and has been prepared for informational purposes only and are not intended to indicate the results of future operations or the financial position of either company.

 

The historical financial statements have been adjusted in the unaudited pro forma condensed combined financial information to give pro forma effect to events that are directly attributable to the Acquisition, factually supportable, and with respect to the statements of operations, expected to have a continuing impact on the results of the Company.

 

The following items are presented as reclassifications in the unaudited pro forma condensed combined financial statements:

 

  (a) Adjustment includes preliminary estimated fair value of intangible assets acquired from InfiniClone.
     
  (b) Adjustment reflects preliminary estimated goodwill.
     
  (c) Adjustment reflects the preliminary estimated fair value of the common shares issued to InfiniClone’s equity holders. This equity consideration is included in the preliminary estimated fair value of the consideration transferred in the Acquisition.
     
  (d) Adjustment includes the elimination of the historical additional paid-in capital and accumulated deficit of InfiniClone.
     
  (e) Represents pro forma adjustment to eliminate transaction expenses related to the Acquisition incurred by the Company and InfiniClone, which will not be recurring after the completion of the Acquisition.

 

 

 

 

  (f) Adjustment includes preliminary estimated fair value of property and equipment acquired from InfiniClone.
     
  (g) Adjustment includes the cumulative impact of preliminary depreciation or amortization expense for property and equipment acquired.
     
  (h) Adjustment includes the cumulative impact of the amortization of identifiable intangible assets.
     
  (i) Accrued consideration payable to the original shareholder of InfiniClone for the business acquisition.
     
  (j) To record the increase of deferred tax liabilities as a result of the increase in value of property and equipment, and intangible assets, which may be taxable in the future.
     
  (k) Adjustment reflects portion of net assets of InfiniClone attributable to non-controlling interest.
     
  (l) Increase in the weighted average shares in connection with the issuance of 3,450,000 common shares as the consideration of the acquisition.
     
  (m) To record the reversal of deferred tax liabilities as a result of the depreciation or amortization of property and equipment and identifiable intangible assets.
     
  (n) Adjustment reflects portion of comprehensive income (loss) of InfiniClone attributable to non-controlling interest.